Covenant Just Priced a Cruise Missile at Mid-Six Figures — RTX's $22.9B Tomahawk Deal Is Now the Cushion, Not the Answer

Covenant — a 200-person defense startup founded in 2024, with production already running in Germany and northern Israel — broke cover on Sep 9, 2026 with a 105,000-square-foot Dallas factory and a long-range, heavy-payload cruise missile called Anthem. The company is targeting mid-six-figure pricing per missile at full-rate production, alongside a $250M+ raise and two Department of Defense awards inked the same day. The math doesn't look like legacy defense.

RTX's Raytheon segment owns the cruise-missile category. Tomahawk is a 1,000-mile-class weapon with a per-unit cost that ranges from about $1.5M for older blocks to $3.6M for the latest Block V in FY2026 Navy procurement. The Aug 17, 2026 $22.9B seven-year contract — RTX's largest Tomahawk award on record — pushes production beyond1,000 rounds a year and a 3x delivery pace versus H1 2025. The new math bends both sides of the equation at once: Anthem undercuts price by2–6x and over-shoots planned output by ~12x.

Covenant is not standing alone. The two-year-old startup's Sep 9 announcement lands inside a cohort that has raised more than $35B of private capital across 2026, all oriented toward rebuilding U.S. defense manufacturing capacity with software-native and factory-native discipline. a16z and Peter Thiel's Founders Fund are core backers of Covenant, and Anduril, Castelion and Hadrian together have already moved from thesis to balance sheet in the past eight months.

Covenant is the cruise-missile beachhead of this group. The same playbook applies — COTS components, software-first mission systems, automated factories built in months rather than years — and the cohort is now producing the kind of volume figures that historically required a Lockheed Martin or Raytheon program of record to justify.

RTX sits on a record $289B total backlog as of Q2 FY2026, including $119B of defense orders and an additional $170B of commercial aerospace work — up 22% year-over-year and6% sequentially. Q2 revenue of $24.7B (+16% YoY) is being supported by accelerating Tomahawk output, and the $22.9B seven-year Navy deal converts into roughly $3.3B in annual missile revenue at run-rate. The defense backlog covers years of cushioned demand; the medium-term question is what RTX is buying with the cash flow that contract generates, and whether it acquires, partners or builds a software-cohort answer.

Lockheed Martin's Missiles and Fire Control segment is the second direct exposure — it owns a portfolio that competes with both Tomahawk-class cruise missiles and tactical strike munitions — and Northrop Grumman's Defense Systems unit is the third, with propulsion and hypersonic-strike work feeding the same long-range-strike demand pool. Neither prime has Anthem-style economics; neither needs them in the next 24 months, but the long-cycle math is harder to ignore when a $250M cohort can produce 12,000 missiles a year at a third of the price.

Covenant's announcement doesn't only reshape prime missile economics — it pulls forward demand across the broader defense-manufacturing supply chain. Hadrian's automated factories, where it already supplies Anduril and primes, sit on the upstream side; HEICO's aerospace components, Curtiss-Wright's defense electronics and naval subsystems and Rocket Lab's space-grade hardware and launch sit one tier closer to prime platforms. The cohort's playbook — COTS parts, software-defined production — expands the addressable market for components suppliers that can meet defense qualification without prime-grade overhead.

The through-line is that software-defined defense is layered: Palantir-style data and command-and-control at the top, Anduril and Kratos autonomous systems in the middle, cruise-missile volume from Covenant at the strike tier, and COTS-grade components flowing through HEICO and Curtiss-Wright underneath. Each layer pulls the next one forward; each is also exposed to the risk that prime margins get re-priced as the cohort scales.

Short-term (days to quarters). The Sep 9 announcement and the Q1 2027 Dallas serial-production start are the load-bearing dates. Each milestone — first serial unit off the line, first Army qualification flight under the new OTA, first Navy Maritime variant test — moves the cohort from stealth to revenue. Watch the next funding round in this group: Castelion's $1B Series C closed Aug 19, 2026 and Hadrian's $1.37B Series D closed the same month; a Covenant Series C at the same scale would lock in the cohort's cruise-missile credibility and put the category inside the public-market IPO conversation.

Long-term (one to three years). The structural read is that the U.S. cruise-missile market bifurcates: a high-end Tomahawk tier that stays with RTX (priced at $2–3.6M a shot, defended by Navy doctrine and existing $22.9B of backlog), and a high-volume, mid-six-figure tier that the cohort owns. If Anthem hits even a fraction of its 12,000-missile combined capacity and price target, the volume tier alone is a $7B-plus annual revenue category — comparable to the entire Northrop Grumman Defense Systems segment. The investors' question is whether that category ever gets priced by public markets as a stand-alone business, or whether it ends up acquired by a prime that needs the volume tier to defend its $119B defense backlog.